263 related articles for article (PubMed ID: 31137964)
21. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
24. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
Nikolaenko L; Liu T; Danilov AV
Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685
[No Abstract] [Full Text] [Related]
25. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.
Izutsu K; Kato K; Kiyoi H; Yamamoto G; Shimada K; Akashi K
Int J Hematol; 2020 Oct; 112(4):504-509. PubMed ID: 32613313
[TBL] [Abstract][Full Text] [Related]
26. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Dong S; Guinn D; Dubovsky JA; Zhong Y; Lehman A; Kutok J; Woyach JA; Byrd JC; Johnson AJ
Blood; 2014 Dec; 124(24):3583-6. PubMed ID: 25258342
[TBL] [Abstract][Full Text] [Related]
27. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
28. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Solman IG; Blum LK; Hoh HY; Kipps TJ; Burger JA; Barrientos JC; O'Brien S; Mulligan SP; Kay NE; Hillmen P; Byrd JC; Lal ID; Dean JP; Mongan A
Leuk Res; 2020 Oct; 97():106432. PubMed ID: 32911375
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
31. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
32. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
34. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
[TBL] [Abstract][Full Text] [Related]
35. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Hanlon A; Brander DM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
[TBL] [Abstract][Full Text] [Related]
36. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
de Weerdt I; Koopmans SM; Kater AP; van Gelder M
Haematologica; 2017 Oct; 102(10):1629-1639. PubMed ID: 28775119
[TBL] [Abstract][Full Text] [Related]
37. A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Davids MS; Fisher DC; Tyekucheva S; McDonough M; Hanna J; Lee B; Francoeur K; Montegaard J; Odejide O; Armand P; Arnason J; Brown JR
Leukemia; 2021 Apr; 35(4):1064-1072. PubMed ID: 32820271
[TBL] [Abstract][Full Text] [Related]
38. Duvelisib: First Global Approval.
Blair HA
Drugs; 2018 Nov; 78(17):1847-1853. PubMed ID: 30430368
[TBL] [Abstract][Full Text] [Related]
39. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
40. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Gordon MJ; Churnetski M; Alqahtani H; Rivera X; Kittai A; Amrock SM; James S; Hoff S; Manda S; Spurgeon SE; Choi M; Cohen JB; Persky D; Danilov AV
Cancer; 2018 Aug; 124(15):3192-3200. PubMed ID: 29797667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
